Hepatology International

, Volume 5, Issue 2, pp 644–653

HBV life cycle and novel drug targets

Review Article

DOI: 10.1007/s12072-011-9261-3

Cite this article as:
Grimm, D., Thimme, R. & Blum, H.E. Hepatol Int (2011) 5: 644. doi:10.1007/s12072-011-9261-3


With up to 400 million affected people worldwide, chronic hepatitis B virus (HBV) infection is still a major health care problem. During the last decade, several novel therapeutic approaches have been developed and evaluated. In most regions of the world, interferon-α, and nucleos(t)ide analogues (NUCs) are currently approved. Despite major improvements, none of the existing therapies is optimal since viral clearance is rarely achieved. Recently, a better understanding of the HBV life cycle and the development of novel model systems of HBV infection have led to the development of novel antiviral strategies and drug targets. This review will focus on current and potential future drug targets in the HBV life cycle and strategies to modulate the virus–host interaction.


HBV life cycle

Copyright information

© Asian Pacific Association for the Study of the Liver 2011

Authors and Affiliations

  1. 1.Department of Medicine IIUniversity of FreiburgFreiburgGermany